Bioalmanac
Mazdutide
IBI362 · LY3305677
A GLP-1 and glucagon dual agonist approved in China in 2026. Not approved in the United States, and the US pathway is undecided.
Storage
- Freeze-dried powder
- Refrigerated at 2–8 °C, protected from light.
- After mixing
- Refrigerated at 2–8 °C. Do not freeze once mixed.
- Long-term, frozen
- Unopened powder is stable at −20 °C or colder.
Reconstitution — 10 mg vial, 6000 mcg dose
On a 1 mL U-100 syringe. Check every figure against your own vial before drawing.
| Water added | Concentration | Volume to draw | Units | Doses per vial |
|---|---|---|---|---|
| 1 mL | 10 mg/mL | 0.6 mL | 60 units | 1.7 |
| 2 mL | 5 mg/mL | — | Exceeds a 1 mL barrel | — |
| 3 mL | 3.333 mg/mL | — | Exceeds a 1 mL barrel | — |
| 5 mL | 2 mg/mL | — | Exceeds a 1 mL barrel | — |
Dose ranges reported in sources
Descriptions of what sources report, not recommendations.
| Goal | Range | Frequency | Source |
|---|---|---|---|
| Phase 3 dosing for weight management | 4000–6000 mcg | Once weekly, reached by escalation | Clinical trial |
When to stop
- Severe, persistent abdominal pain, particularly radiating to the back.
- Vomiting severe enough that you cannot keep fluids down.
- A resting heart rate that is persistently higher than usual, or palpitations.
- Any allergic response: rash, hives, facial swelling or difficulty breathing. Seek urgent care.
- Signs of low blood sugar if you also use insulin or a sulfonylurea.
Use your browser’s print dialog and choose “Save as PDF”. This block is hidden when printed.